FLT3 and acute myeloid leukemia: In another randomized phase III study comparing post-ASCT sorafenib maintenance (n = 100) to non-maintenance (n = 102), sorafenib demonstrated an improved 1-year OS (82.1% vs 68%, P = 0.012) and a decreased 1-year cumulative incidence of relapse (7% vs 24.5%, P = 0.001) in FLT3-ITDmut AML patients undergoing ASCT in CR143.